title: Comment on: Bono P, Oudard S, Bodrogi I, et al. Outcomes in Patients With Metastatic Renal Cell Carcinoma Who Develop Everolimus-Related Hyperglycemia and Hypercholesterolemia: Combined Subgroup Analyses of the RECORD-1 and REACT Trials. Clin Genitourin Cancer 2016.
authors.affiliation: Buckinghamshire, UK. Electronic address: clinical.safety@hotmail.co.uk.
authors.forename: Rashmi R
authors.initials: RR
authors.lastname: Shah
mesh_terms: D000970:Antineoplastic Agents; D002292:Carcinoma, Renal Cell; D000068338:Everolimus; D006801:Humans; D006937:Hypercholesterolemia; D006943:Hyperglycemia; D007680:Kidney Neoplasms
chemical_list: D000970:Antineoplastic Agents; D000068338:Everolimus
keywords: Cancer outcomes; Metformin; mTOR inhibition